University of California San Francisco
Give to UCSF
In a finding that once again displays the power of the female, UCSF neuroscientists have discovered that teenage male songbirds, still working to perfect their song, improve their performance in the presence of a female bird.
Among those cheering the recent opening of the new stem cell science building at UCSF were two patient advocates who have a personal connection to advancing the field of regenerative medicine.
UCSF neuroscientists are exploring the way in which songbirds learn to perfect and maintain their song, a model of how one learns — and might relearn — fine motor skills.
A documentary debuting today shows how UCSF researchers are using innovative multidisciplinary treatment strategies for patients living with Parkinson’s disease.
A medication commonly prescribed as a muscle relaxant shows promise as a potential treatment for alcoholism, based on a study in rats by researchers at the Ernest Gallo Clinic and Research Center and the University of California, San Francisco.
Parkinson’s disease researcher Robert Nussbaum, a human geneticist and neuroscientist at UCSF, has been named to receive the prestigious Klaus Joachim Zülch Neuroscience Prize for 2011.
For patients with glioma, the most common primary brain tumor, new findings may explain why current therapies fail to eradicate the cancer. A UCSF-led team of scientists has identified for the first time that progenitor rather than neural stem cells underly a type of glioma called oligodendroglioma.
UCSF’s Stanley Prusiner, who received the National Medal of Science from President Barack Obama on Wednesday, urges today’s students to become the next generation of scientists.
UCSF researchers have for the first time shown that an external optical pacemaker can be used in a vertebrate to control its heart rate.
UCSF Nobel laureate Stanley Prusiner, MD, and colleagues have called for Congress to more than quadruple annual federal funding for Alzheimer’s research, saying that with a dedicated effort, there is a chance for a breakthrough against the disease by 2020.
Researchers at the Ernest Gallo Clinic and Research Center at UCSF, and Pfizer Inc., have determined that two new compounds may be effective in treating both alcohol and nicotine dependence at the same time.
Rapamycin, an FDA-approved drug prescribed to prevent the rejection of transplanted organs, has been shown for the first time to decrease excessive alcohol consumption, binge drinking, and alcohol-seeking behavior in rodents.